HAI-ROBOTICS
27.12.2021 10:09:04 CET | Business Wire | Press release
HAI ROBOTICS , a global leader in Autonomous Case-handling Robotics (ACR) systems for warehouse order fulfillment, is celebrating its fifth anniversary at its new headquarters as it ranks among global unicorns according to this year’s unicorn ranking list from the Hurun Research Institute.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211226005013/en/
The company, a logistics warehousing automation solution provider that secured three rounds of funding in 2021, was nominated along with 300 other Chinese start-ups which were valued at more than US$1 billion as of November this year in a global list totaling 1,058. The list was released last week.
HAI ROBOTICS was founded in late 2016 by a group of like-minded robot enthusiasts who aspire to create value for every warehouse and factory with the vision to push forward human civilization through robotics technology. The company’s birth originated from a revolutionary idea that took shape as early as 2015 – the totes-to-person solution – to improve warehouse operational efficiency, instead of creating a homogenous brand of the then prevalent shelves-to-person material handling.
The solution underwent repeated tests and trials in a real warehouse environment for nearly two years before it was formally introduced into the market. The company’s first project was successfully deployed in Best Logistics’ warehouse in August 2018. Soon the story went viral with great exemplary effect that the ACR solution swiftly secured footholds in factories and warehouses.
“It’s an extraordinary journey for us to grow from the cradle of a small workshop into a company of more than 1,200 employees with five branch offices across the globe today,” said Richie Chen, the company’s founder and CEO. “We’re celebrating our fifth anniversary with gratitude to our customers and investors for their trust and confidence in our team. We’ll keep making innovative products and stay committed to bringing value to our partners.”
Automating a warehouse can be a huge project worthy of careful consideration for any business operator. The concerns could range from the length of necessary deployment time, agility of refitting, affordability to ROIs. The HAI ROBOTICS team kept their users’ concerns in mind when building their products. Hence, they kept refining their ideas and fine-tuning the HAIPICK robots for wider applications and stricter storage requirements.
First and foremost, the HAIPICK ACR solution allows greater space utilization and higher goods-handling precision and efficiency than traditional Goods-to-Person solutions, such as Kiva robots that move an entire rack. With the HAIPICK ACR solution, a warehouse’s storage density can be boosted by 80% to 400% and a worker’s picking speed can be improved 3 to 4 times. In addition, the HAIPICK robots, using QR codes on the floor for navigation, can be deployed within one month with no altering of the interior structure of a warehouse.
Thanks to its easy deployment and flexibility, the solution has been adopted by a wide array of customers who prefer smaller picking units than an entire rack or pallet when automating their warehouses. So far, HAI ROBOTICS has been running more than 300 projects globally in various fields, including e-commerce, 3PL, apparel, electronics, energy, manufacturing, medicine, and more. To provide localized service overseas, it has partnered with dozens of global logistics and supply chain leaders, including LG CNS, MHS, MUJIN, BPS, Savoye, Invar, SSI Schaefer and more.
About HAI ROBOTICS
HAI ROBOTICS, a trailblazer of Autonomous Case-handling Robot (ACR) systems, is committed to providing efficient, intelligent, flexible, and customized warehouse automation solutions through robotics technology and AI algorithms. It aims to create value for each factory and logistics warehouse.
The HAIPICK ACR system, independently developed in 2015, is the world's first of its kind.
Founded in 2016 with headquarters in Shenzhen, China, HAI ROBOTICS has set up five subsidiaries in Hong Kong SAR, Japan, Singapore, the U.S. and the Netherlands, serving customers from more than 30 countries and regions. It now has over 1,200 staff, more than 50% of whom are engineers. The company has acquired more than 600 global patents for core intellectual properties involving positioning, robot control and warehouse management. In the latest C and D rounds of funding in 2021, the company raised over US$200 million in total.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211226005013/en/
Link:
Social Media:
https://www.facebook.com/HAIROBOTICS/videos/?ref=page_internal
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
